Roth Capital Reiterates Buy Rating on Inmed Pharmaceuticals (INM) After Missing EPS
Tweet Send to a Friend
Roth Capital analyst Scott Henry reiterated a Buy rating and $11.50 price target on Inmed Pharmaceuticals (NASDAQ: INM) after the ...
This is a premium only article. To continue reading this and other premium stock market news articles please sign-in or upgrade to StreetInsider.com Premium below (Free Trial) LEARN MORE
This is a premium only article. To continue reading this and other premium stock market news articles please sign-in or upgrade to StreetInsider.com Premium below (Free Trial) LEARN MORE
